Find the right fit for you - faster
Get tailored insights about working at Pulmonx in one quick step.
Pulmonx Snapshot
OUR MISSION
To be the global leader and trusted partner in assessment and treatment of severe lung disease by innovating and commercializing evidence-based solutions to improve patients’ breathing and quality of life.
OUR VALUES
Patient Focus: We put the best interest of our patients at the center of our decisions, and seek to delight our customers as we partner to serve patients.
Innovation: We adapt quickly, and continuously seek new ways to create value for our customers, employees, and shareholders.
Science: We take a data-driven approach to decision making, clinical strategy, and commercial execution.
Global Collaboration: We seek diverse perspectives and teams that work respectfully across geographies and functions to bring our innovations to patients around the world.
Accountability: We deliver on our commitments with integrity, transparency, sound judgement, and a sense of urgency.
To be the global leader and trusted partner in assessment and treatment of severe lung disease by innovating and commercializing evidence-based solutions to improve patients’ breathing and quality of life.
OUR VALUES
Patient Focus: We put the best interest of our patients at the center of our decisions, and seek to delight our customers as we partner to serve patients.
Innovation: We adapt quickly, and continuously seek new ways to create value for our customers, employees, and shareholders.
Science: We take a data-driven approach to decision making, clinical strategy, and commercial execution.
Global Collaboration: We seek diverse perspectives and teams that work respectfully across geographies and functions to bring our innovations to patients around the world.
Accountability: We deliver on our commitments with integrity, transparency, sound judgement, and a sense of urgency.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is the maker of the Zephyr Endobronchial Valve. The Zephyr® Valve was granted breakthrough status and approved by the FDA in June 2018, because according to the FDA it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers a significant, clinically meaningful advantage over the current standard of care and therefore, its availability is also in the best interest of patients.”
